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Abstract
Aims N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the most frequently used biomarker in heart failure (HF), but
its prognostic utility across ethnicities is unclear.
Methods and results This study included 546 Caucasians with HF from the Coordinating Study Evaluating Outcomes of Ad-
vising and Counseling in Heart Failure and 578 Asians with HF from the Singapore Heart Failure Outcomes and Phenotypes
study. NT-proBNP was measured at discharge after HF hospitalization. The studied outcome was a composite of all-cause mor-
tality and HF hospitalization at 18 months. Compared with Caucasian patients, Asian patients were younger (63 ± 12 vs.
71 ± 11 years); less often female (26% vs. 39%); and had lower body mass index (26 vs. 27 kg/m2), better renal function
(61 ± 37 vs. 54 ± 20 mL/min/1.73 m2), lower rates of atrial ﬁbrillation (25% vs. 46%), strikingly higher rates of diabetes
(59% vs. 30%), and higher rates of hypertension (76% vs. 44%). Despite these clear inter-group differences in individual drivers
of NT-proBNP, average levels were similar in Asians [2709 (1350, 6302) pg/mL] and Caucasians [2545 (1308, 5484) pg/mL]
(P = 0.514). NT-proBNP was strongly associated with outcome [hazard ratio 1.28 (per doubling), 95% conﬁdence interval
1.18–1.39, P< 0.001], regardless of ethnicity (Pinteraction = 0.719). NT-proBNP was similarly associated with outcome in HF with
reduced and preserved ejection fraction in Asian (Pinteraction = 0.776) and Caucasian patients (Pinteraction = 0.558).
Conclusions NT-proBNP has similar prognostic performance in Asians and Caucasians with HF despite ethnic differences in
known clinical determinants of plasma NT-proBNP.
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Introduction
Inter-ethnic differences in the incidence, symptoms, underlying
pathophysiology, and treatment of heart failure (HF) have been
described.1–4 However, most epidemiological studies and ther-
apeutic trials have focused exclusively on Caucasian popula-
tions, and available data on HF in Asian populations are scarce.5
Previously, Asian HF patients have been reported to have
lower mortality rates than did their Caucasian peers.6 Higher
rates of HF with a preserved ejection fraction (HFpEF) within
Asian patients together with higher rates of co-morbidities
such as hypertension, with lower rates of documented
myocardial infarction, have also been claimed.7
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is
the best-validated biomarker in risk stratiﬁcation and man-
agement of HF.8–10 B-type cardiac natriuretic peptide (BNP)
and NT-proBNP have proven their prognostic power in pa-
tients with HF across the entire spectrum of ejection
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fraction.11 A recent study showed that Asian-American and
African-American HF patients have higher BNP levels than
did their Caucasian peers and that predictive value for in-
hospital mortality was similar between ethnicities in an acute
HF population.12 Furthermore, NT-proBNP had higher discrim-
inatory power for identifying HF in Asian dyspnoeic individuals
in the emergency department than in Caucasian dyspnoeic in-
dividuals.13 However, no previous reports compare results
from multi-ethnic populations with those from stable HF in
Asian and Western settings. Therefore, we report the clinical
associations and prognostic performance of NT-proBNP in
Asian and Caucasian patients with chronic HF.
Methods
Study design and population
Data were combined from the studies of Coordinating Study
Evaluating Outcomes of Advising and Counseling in Heart
Failure (COACH) and the Singapore Heart Failure Outcomes
and Phenotypes (SHOP).14–16
In brief, the COACH trial studied the effects of additional
intensive nurse-led support on clinical outcomes in 1023 HF
patients.15 Overall, the results of the trial were neutral.14
NT-proBNP measurements were available in a sub-cohort of
546 Caucasian patients measured at discharge (see
Supporting Information, Figure S1). The SHOP study prospec-
tively enrolled 1099 HF patients from six different centres in
Singapore. The main objective of the SHOP study is to docu-
ment the prevalence, characteristics, and outcomes of Asian
HF patients in Singapore and to determine the relative pro-
portion of HFpEF patients in this population.16 The Asian pop-
ulation used in this study refers to a SHOP sub-cohort of 578
patients with NT-proBNP measurements available at dis-
charge following hospitalization (see Supporting Information,
Figure S1). Inclusion and exclusion criteria were similar for
both studies, which both included patients >18 years of
age, either presenting as new onset HF or having previous
HF hospitalizations.15,16 In both studies, blood sampling for
NT-proBNP assay was performed at or around discharge after
hospitalization for acute decompensated HF.15,16 Only partic-
ipants recruited as inpatients were included in this report.
This study complies with the Declaration of Helsinki, local
medical ethics committees approved the study, and all pa-
tients provided written informed consent.
Outcome
The endpoint analysed was a combined outcome of all-cause
mortality or HF hospitalizations within 18 months. In both
studies, endpoints were adjudicated by an independent
committee.
Study and laboratory measurements
Blood samples, echocardiography, and all other data were
obtained at discharge from index hospitalization for both
COACH and SHOP. HFpEF was deﬁned by a left ventricular
ejection fraction (LVEF) of ≥50%, and heart failure with a re-
duced ejection fraction (HFrEF) by an LVEF < 40%. Recently,
patients with an intermediate LVEF (HF with a mid-range
ejection fraction) have been considered to be a speciﬁc pa-
tient group and were, therefore, left out of the deﬁnition of
HFrEF and HFpEF but were included in the analyses on the
total population in this study.17 Assessment of LVEF was per-
formed at admission or within 6 months prior to admission.
Measurements of NT-proBNP were performed on the Elecsys
proBNP ECLIA platform (Roche Diagnostics, Mannheim,
Germany) in both the SHOP and COACH cohorts. This assay
has intra-assay and inter-assay coefﬁcients of variation of
4% and 5%, respectively. The estimated glomerular ﬁltration
rate (eGFR) was calculated using the Modiﬁcation of Diet in
Renal Disease formula.18
Statistical analysis
Continuous variables are presented as medians with inter-
quartile range or means ± SD, where appropriate. Categorical
variables are presented as numbers with percentages. Inter-
group differences were tested using Student’s t-test or
Mann–Whitney U-test for continuous variables or χ2 test for
categorical variables.
We compared absolute values of NT-proBNP between eth-
nicities. For all subsequent (Cox) regression analysis, NT-
proBNP was log2 transformed. The following results for NT-
proBNP should be interpreted as per doubling (e.g. 2–4 and
4–8). An interaction analysis was performed to assess if the
relationship between individual clinical variables and NT-
proBNP levels differed between ethnicities. Univariable linear
regression analysis was performed separately for Caucasians
and Asians with NT-proBNP as the dependent variable. Multi-
variable adjustment was then performed for factors known to
inﬂuence NT-proBNP levels including age, sex, body mass in-
dex (BMI), LVEF, New York Heart Association class, previous
myocardial infarction, systolic blood pressure, a history of
atrial ﬁbrillation, and eGFR.19–24
Cox regression analysis (including interaction analysis in
univariable and multivariable models) was performed to
further investigate the possible differential association of
NT-proBNP with outcome between different ethnicities.
Multivariable models were produced based on signiﬁcant dif-
ferences at baseline between ethnicities as well as incorpo-
rating known clinically meaningful variables. Model ﬁt was
tested using the Hosmer–Lemeshow goodness-of-ﬁt test.
Additionally, to graphically depict the relationship between
ethnicity and the primary outcome, Kaplan–Meier curves
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stratiﬁed by ethnicity were produced. Differences were tested
using the log-rank test. For multivariable Cox regression anal-
ysis, the proportional hazards assumption was tested using
Schoenfeld residuals and found to be valid. We have provided
results of continuous net reclassiﬁcation analysis to study
whether NT-proBNP signiﬁcantly improves a model of clinical
variables equally in Asian and Caucasian HF patients. Further-
more, we studied the ability of NT-proBNP to predict outcome
on top of a clinical model using the area under the receiver
operating characteristic curve. Tests were performed two
sided, and a P-value of <0.05 was considered signiﬁcant. All
statistical analyses were performed using STATA version 13.0
(StataCorp LP, College Station, Texas, USA).
Results
Baseline characteristics
Baseline demographic and clinical characteristics of Asian and
Caucasian patients are presented in Table 1. Asian patients
were younger and less often female than were their Cauca-
sian peers. Additionally, Asian patients had a lower BMI and
a better renal function and an overall lower burden of chronic
obstructive pulmonary disease, atrial ﬁbrillation, and
peripheral vascular disease, while having higher rates of
diabetes mellitus and hypertension (Table 1). Furthermore,
Asian HF patients were more often treated with beta-
blockers (Table 1). Despite these differences, absolute plasma
concentrations of NT-proBNP in Asian and Caucasian patients
were similar (P = 0.514; Figure 1). After correcting for clinical
characteristics inﬂuencing NT-proBNP levels including age,
sex, BMI, eGFR, systolic blood pressure, history of atrial ﬁbril-
lation, and usage of angiotensin-converting enzyme inhibi-
tors, diuretics, and beta-blockers, NT-proBNP levels were
equal between Caucasians and Asians (β = 0.045, P = 0.161,
for Asian compared with Caucasian HF patients).
N-terminal pro-B-type natriuretic peptide and
clinical variables
Univariable and multivariable associations between levels of
NT-proBNP and clinical variables are shown in Table 2. In
univariable analysis, NT-proBNP levels were more strongly as-
sociated with the male sex in Asians than in Caucasians
Table 1 Baseline characteristics
Total cohort (n = 1124) Caucasian (n = 546) Asian (n = 578) P value
Demographics
Age (years) 66.9 (12.3) 70.7 (11.2) 63.2 (12.3) <0.001
Female sex, n (%) 362 (32.1%) 210 (38.5%) 152 (26.3%) <0.001
NYHA class, n (%) I/II 689 (62.2%) 257 (47.4%) 432 (76.3%) <0.001
III 391 (35.3%) 271 (50.0%) 120 (21.2%)
IV 28 (2.5%) 14 (2.6%) 14 (2.5%)
BMI (kg/m2) 26.6 (5.5) 27.1 (5.5) 26.1 (5.5) 0.004
Systolic blood pressure (mmHg) 119.3 (20.2) 118.1 (21.0) 120.3 (19.3) 0.066
Diastolic blood pressure (mmHg) 68.9 (12.1) 68.6 (12.2) 69.2 (12.1) 0.43
Heart rate (b.p.m.) 76.0 (13.9) 74.6 (13.3) 77.4 (14.3) <0.001
LVEF (%) 29.0 (20.0, 42.0) 30.0 (22.0, 40.0) 28.0 (20.0, 45.0) 0.990
HFpEF, n (%) 169 (18.5%) 49 (12.7%) 118 (22.5%) <0.001
Medical history, n (%)
Myocardial infarction 388 (39.7%) 215 (39.4%) 173 (40.0%) 0.830
Hypertension 676 (60.4%) 240 (44.0%) 436 (76.1%) <0.001
COPD 194 (17.3%) 147 (26.9%) 47 (8.2%) <0.001
Atrial ﬁbrillation 394 (35.2%) 251 (46.0%) 143 (24.9%) <0.001
Diabetes mellitus 503 (44.8%) 162 (29.7%) 341 (59.2%) <0.001
Peripheral vascular disease 130 (11.6%) 91 (16.7%) 39 (6.8%) <0.001
Stroke 147 (13.1%) 83 (15.2%) 64 (11.1%) 0.040
Prior medication, n (%)
ACE-inhibitors 723 (65.0%) 394 (72.2%) 329 (58.1%) <0.001
ARB 203 (18.3%) 62 (11.4%) 141 (24.9%) <0.001
ACE-inhibitors and/or ARB 911 (81.9%) 449 (82.2%) 462 (81.6%) 0.790
Beta-blocker 861 (77.4%) 372 (68.1%) 489 (86.4%) <0.001
Aldosterone antagonists 535 (48.1%) 296 (54.2%) 239 (42.2%) <0.001
Diuretics 1039 (93.4%) 522 (95.6%) 517 (91.3%) 0.004
Digoxin 325 (29.2%) 177 (32.4%) 148 (26.1%) 0.022
Laboratory
eGFR (mL/min/1.73 m2) 57.8 (30.2) 54.1 (19.6) 61.3 (37.1) <0.001
Potassium (mEq/L) 4.1 (3.8, 4.5) 4.2 (3.9, 4.6) 4.0 (3.7, 4.4) <0.001
Sodium (mEq/L) 138.0 (136.0, 141.0) 139.0 (136.0, 142.0) 138.0 (136.0, 140.0) <0.001
ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary
disease; eGFR, estimated glomerular ﬁltration rate; HFpEF, heart failure with a preserved ejection fraction; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association. Data in bold are P-values <0.05.
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(β = 0.033, P = 0.442, in Caucasians; β = 0.137, P = 0.001,
in Asians; Pinteraction = 0.046); however, no difference in levels
of NT-proBNP between sexes were observed after correcting
for the presence of HFpEF in both Asians and Caucasians.
Equal associations were found between levels of NT-proBNP
and clinical covariates such as a history of atrial ﬁbrillation,
hypertension, BMI, LVEF, and eGFR in both Asians and Cauca-
sians (Pinteraction all >0.05). The R
2 for the multivariable
model in Caucasian HF patients (0.17) was lower than in
Asian HF patients (0.29).
Outcome in Asian and Caucasian heart failure
patients
In the entire cohort, 507 (45%) patients [including 273 (47%)
Asians] incurred the primary composite outcome. Asian pa-
tients reached the primary combined outcome of all-cause
mortality or HF hospitalizations at 18 months more often
than did their Caucasian counterparts [hazard ratio (HR)
1.35; 95% conﬁdence interval (CI) 1.13–1.60; P = 0.001]. Also
after multivariable correction, Asian patients were more
Figure 1 Boxplots showing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in Asian and Caucasian heart failure patients.




Univariable Multivariablea Univariable Multivariablea
β (P-value) β (P-value) β (P-value) β (P-value)
Demographics
Age 0.114 (0.008) 0.055 (0.275) 0.108 (0.009) 0.155 (0.001) 0.890
Female sex 0.033 (0.442) 0.014 (0.756) 0.137 (0.001) 0.013 (0.752) 0.046
NYHA class 0.127 (0.003) 0.081 (0.085) 0.140 (0.001) 0.108 (0.004) 0.542
BMI 0.262 (<0.001) 0.188 (<0.001) 0.272 (<0.001) 0.193 (<0.001) 0.588
Heart rate 0.073 (0.091) 0.064 (0.169) 0.045 (0.280) 0.016 (0.678) 0.642
LVEF 0.253 (<0.001) 0.259 (<0.001) 0.345 (<0.001) 0.456 (<0.001) 0.258
HFpEF 0.232 (<0.001) 0.064 (0.457) 0.376 (<0.001) 0.238 (0.007) 0.076
Medical history
Myocardial infarction 0.063 (0.140) 0.029 (0.547) 0.116 (0.015) 0.031 (0.475) 0.361
Peripheral vascular disease 0.055 (0.199) 0.019 (0.685) 0.095 (0.022) 0.090 (0.015) 0.216
Hypertension 0.041 (0.335) 0.073 (0.128) 0.059 (0.158) 0.043 (0.266) 0.087
Atrial ﬁbrillation 0.051 (0.231) 0.033 (0.491) 0.094 (0.023) 0.124 (0.001) 0.323
Diabetes 0.000 (0.991) 0.051 (0.278) 0.020 (0.625) 0.037 (0.327) 0.728
Laboratory
eGFR 0.219 (<0.001) 0.223 (<0.001) 0.223 (<0.001) 0.185 (<0.001) 0.061
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; HFpEF, heart failure with a preserved ejection fraction; LVEF, left ven-
tricular ejection fraction; NYHA, New York Heart Association.
Explanatory note: univariable and multivariable associations for between clinical variables and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) levels are shown. The P-value for interaction is the interaction between ethnicity (Asian and Caucasian) and the clinical var-
iable for the association with NT-proBNP. Data in bold are P-values <0.05.
aCorrected for age, sex, BMI, LVEF, systolic blood pressure, eGFR, and a history of atrial ﬁbrillation.
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often subject to all-cause mortality or HF rehospitalizations
over 18 months (HR 1.36; 95% CI 1.08–1.72; P = 0.009, see
Supporting Information, Table S1 and Figure S2). For all-cause
mortality alone, 154 (28%) Caucasian HF patients died within
18 months compared with 102 (18%) Asian patients
(P < 0.001).
N-terminal pro-B-type natriuretic peptide levels
and outcome
The association of NT-proBNP with the primary combined out-
come was similar (Pinteraction = 0.631) in Asians (HR 1.56; 95% CI
1.29–1.89; P < 0.001) and Caucasians in both unadjusted and
adjusted analyses (HR 1.28; 95% CI 1.21–1.35, Table 3 and
Figure 2; and HR 1.33; 95% CI 1.16–1.54; P < 0.001, Table 3
and Figure 3, respectively). The predictive value of NT-proBNP
in patients with HFrEF and HFpEF was similar in Asian and
Caucasian patients speciﬁcally; NT-proBNP had equal predictive
power in both HFrEF and HFpEF subgroups (Pinteraction > 0.05
across univariable and multivariable models for both Asian
and Caucasians) for the combined outcome of death and HF
hospitalization (Table 3). In multivariable analysis, NT-proBNP
remained equally predictive for the combined endpoint in both
Asian and Caucasian HFrEF and HFpEF patients (see Supporting
Information, Figure S3). Results were similar for all-cause mor-
tality alone (see Supporting Information, Table S2). When ex-
ploring subgroup associations with outcome in both Asian
and Caucasian HF patients, no signiﬁcant differences were
found (P-value for interaction all >0.05; see Supporting
Information, Figures S4 and S5). The receiver operating charac-
teristic curve of the clinical model (Model 3 from Table 3) in-
creased from 0.65 to 0.69 when NT-proBNP was added in
Asian patients (P < 0.001) and from 0.70 to 0.72 in Caucasian
patients (P = 0.037). Net-reclassiﬁcation analysis showed that
both Asian [net reclassiﬁcation index (NRI) 0.377, P < 0.001]
and Caucasian (NRI 0.325, P< 0.001) patients with HF were sig-
niﬁcantly reclassiﬁed after adding NT-proBNP to a model of
clinical variables (Model 3, Table 3).
Discussion
This analysis shows that NT-proBNP is a strong and indepen-
dent predictor of adverse outcome in both Asian and Cauca-
sian HF patients. In a similar clinical setting of stable HF, Asian
HF patients have NT-proBNP similar to that of their Caucasian
peers. For a given relative increase of NT-proBNP, outcome is





P-value interaction (ethnicity) P-value interaction (HF status) P-value interaction (HF status)
Univariable 1.28 (1.21–1.35) <0.001 NA 0.338 0.077
Ethnicity 1.28 (1.21–1.35) <0.001 0.631 NA NA
Model 1 1.26 (1.19–1.33) <0.001 0.520 0.865 0.092
Model 2 1.23 (1.15–1.31) <0.001 0.825 0.411 0.583
Model 3 1.28 (1.18–1.39) <0.001 0.719 0.558 0.776
CI, conﬁdence interval; HF, heart failure; HR, hazard ratio.
Model 1: Ethnicity, Age; Sex.
Model 2: Model 1; body mass index; estimated glomerular ﬁltration rate; systolic blood pressure; history of peripheral vascular disease;
chronic obstructive pulmonary disease; diabetes; atrial ﬁbrillation; myocardial infarction, and New York Heart Association class.
Model 3: Model 2; left ventricular ejection fraction; usage of aldosterone antagonists; diuretics; digoxin; beta-blockers; angiotensin-
converting enzyme inhibitors; angiotensin-II receptor blockers.
aHazard ratios are per doubling of levels of N-terminal pro-B-type natriuretic peptide.
Figure 2 Kaplan–Meier curves showing the relationship of N-terminal pro-B-type natriuretic peptide levels with outcome for the total cohort, Cauca-
sian patients, and Asian patients.
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equally poor in both Asian and Caucasian patients. This holds
true in both HFpEF and HFrEF, regardless of ethnicity.
Additionally, the associations of NT-proBNP with its prime
well-recognized drivers are similar across ethnicities. These
ﬁndings have clinical implications, namely, that a relative
NT-proBNP increase in both Asian and Caucasian patients
can be interpreted similarly. Furthermore, it is likely that
NT-proBNP can be used for selection of patients at high risk
for adverse outcomes amongst both Asian and Caucasian
ethnicities.
In this study, Asian HF patients differed signiﬁcantly from
their Caucasian counterparts. They were younger yet had
more adverse outcomes. With regard to co-morbidities, Asian
patients had signiﬁcantly higher rates of diabetes and hyper-
tension, while having lower rates of renal impairment and
atrial ﬁbrillation. Additionally, they had lower BMIs than did
their Caucasian peers. Similar differences with regard to dia-
betes and atrial ﬁbrillation have been previously observed in
an earlier study involving both Asian and Caucasian sub-
jects.12 Despite greater age and burden of co-morbidities,
we found that Caucasian HF patients performed better on
the primary combined outcome than did Asian HF patients.
Nevertheless, Caucasian HF patients had higher mortality
rates than did their Asian peers, suggesting that the differ-
ence between ethnicities for the combined outcome is
mainly driven by higher HF rehospitalization rates. Higher
mortality rates in Caucasian patients are potentially explained
by the lower rates of beta-blocker usage in the Caucasian pa-
tients in this study. The difference in HF rehospitalizations
can be explained by differences in health-care-seeking behav-
iours as well as differences in dosages and effectiveness of
guideline-directed treatment in Asian HF patients, which de-
serves further study.25–27 Additionally, ethnic differences
can potentially be explained by genetic differences rather
than race per se. Yet in the absence of genetic data, race pro-
vides a good surrogate parameter.28
Median NT-proBNP levels were similar in Asian and
Caucasian HF patients. Also, clinical characteristics known
for inﬂuencing NT-proBNP levels had similar effects. Clinical
determinants of BNP levels have been previously found to
be relatively similar across ethnicities.12 Nevertheless, dis-
criminatory power of NT-proBNP for acute HF is superior in
Asian acute HF patients than in Caucasian acute HF patients
in the emergency department.13 NT-proBNP levels were sim-
ilar in our study between Asian and Caucasian patients de-
spite differences in distribution of key drivers of NT-proBNP
levels between Asians such as atrial ﬁbrillation and BMI. This
suggests that, overall, the drivers of NT-proBNP levels were
balanced between Asian and Caucasian HF patients and that
NT-proBNP is similarly prognostic irrespective of the exact
combination and proportional magnitude of drivers for pro-
duction and clearance of plasma NT-proBNP concentrations.
Nevertheless, uncaptured confounders such as nutritional
status and differences in health-care systems and nutritional
status might inﬂuence NT-proBNP levels.29
NT-proBNP was similarly associated with both HF
rehospitalizations and all-cause mortality across ethnicities.
This ﬁnding is in line with an earlier report in acute HF pa-
tients, in which levels of BNP measured at admission were
found to hold equal predictive value for in-hospital mortality
and length of stay.12 Additionally, several key studies have
evaluated the predictive value of BNP in Asian populations
and showed that BNP is a key predictor of outcomes in these
patients.30–32 Also, NT-proBNP levels had equal predictive
value in both HFpEF and HFrEF. This has been previously
reported in a Caucasian population.11 This suggests that clin-
ical applications of NT-proBNP are similar in both Asian and
Caucasian populations. Interestingly, values of NT-proBNP
have been shown to be higher in patients with HFrEF com-
pared with HFpEF, yet the predictive value of NT-proBNP is
similar.11 Outcome of patients with HFpEF was previously
found to be better than that of patients with HFrEF in the
Figure 3 Receiver operating characteristic curves for a clinical model, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and a clinical
model + NT-proBNP for predicting the primary combined outcome in Asian (A) and Caucasian (B) patients.
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MAGGIC meta-analysis study.33 This might in part be ex-
plained by lower NT-proBNP levels; nevertheless, there might
be different factors currently unknown that are driving the
mortality in HFpEF.34,35 Of note, sensitivity and speciﬁcity
for a given level of NT-proBNP were comparable between
Asian and Caucasian HF patients.
NT-proBNP is equally prognostic in both Asian and Cauca-
sian populations. This is despite striking inter-ethnic differ-
ences in the mean level (e.g. younger age in Asians) or
prevalence (e.g. far more frequent atrial ﬁbrillation in Cauca-
sians) of key background drivers for plasma NT-proBNP. Nota-
bly, each driver exhibits similar strength and slope of
association with NT-proBNP between ethnicities. The ﬁndings
suggest that clinical applications of NT-proBNP measure-
ments in diagnosis and management of HF will be similarly ef-
fective across ethnicities. Secondly, application of NT-proBNP
as an entry criterion for enrichment of event rates in future
trials is equally applicable to Caucasians and Asians. With eth-
nic differences with regard to treatment response and out-
come becoming ever more apparent, future HF trials will
most probably be more inclusive of non-western ethnicities.
The ﬁndings of this study suggest that NT-proBNP is equally
valuable as an epidemiologic and clinical tool in both Asian
and Caucasian HF patients.
Limitations
This study is a post hoc analysis with all limitations coming
with that, including potential selection bias. Since no data
are available on treatment during admission for HF prior to
discharge, this might confound some of the reported ﬁndings.
No information was available on difference in nutritional sta-
tus, although differences in health-care systems between
Singapore and the Netherlands might have inﬂuenced NT-
proBNP levels. In this context, patients in this study cover a
grey area between acute decompensated and chronic HF pa-
tients. Corroboration of our ﬁndings will require further stud-
ies in independent Asian and Caucasian HF cohorts.
Conclusions
NT-proBNP has equal predictive power in both Caucasian and
Asian HF populations at discharge after admission for acute
HF. Clinical associations with NT-proBNP do not differ be-
tween ethnicities, suggesting that a given value can be simi-
larly interpreted in both Asian and Caucasian HF patients.
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